Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness-Reference-Cited by-同舟云学术

Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness

Published:2017-03-09 Issue:7 Volume:109 Page:
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Rojas Paola A.¹,May María¹,Sequeira Gonzalo R.¹,Elia Andrés¹,Alvarez Michelle¹,Martínez Paula¹,Gonzalez Pedro¹,Hewitt Stephen¹,He Xiaping¹,Perou Charles M.¹,Molinolo Alfredo¹,Gibbons Luz¹,Abba Martin C.¹,Gass Hugo¹,Lanari Claudia¹

Affiliation:

1. Affiliations of authors: Laboratory of Hormonal Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina (PAR, MM, GS, AE, MA, CL); Hospital de Agudos Magdalena V de Martínez, General Pacheco, Buenos Aires, Argentina (PM, PG, HG); Center for Cancer Research, National Cancer Institute, Bethesda, MD (SH); Department

Funder

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/109/7/djw317/25422452/djw317.pdf

Reference53 articles.

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial;Rossouw;JAMA,2002

2. Breast cancer and hormone-replacement therapy in the Million Women Study;Beral;Lancet,2003

3. Progesterone receptor isoforms A and B: Temporal and spatial differences in expression during murine mammary gland development;Aupperlee;Endocrinology,2005